Haemagglutinin stability was not the primary cause of the reduced effectiveness of live attenuated influenza vaccine against A/H1N1pdm09 viruses in the 2013–2014 and 2015–2016 seasons

During the 2013–2014 influenza season, the quadrivalent live attenuated influenza vaccine (QLAIV), had lower than expected vaccine effectiveness (VE) against circulating A/H1N1pdm09 viruses in the USA. The underlying reason proposed for this was that the A/H1N1pdm09 vaccine strain, A/California/07/2...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2019-07, Vol.37 (32), p.4543-4550
Hauptverfasser: Parker, Lauren, Ritter, Lydia, Wu, Wen, Maeso, Ruben, Bright, Helen, Dibben, Oliver
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4550
container_issue 32
container_start_page 4543
container_title Vaccine
container_volume 37
creator Parker, Lauren
Ritter, Lydia
Wu, Wen
Maeso, Ruben
Bright, Helen
Dibben, Oliver
description During the 2013–2014 influenza season, the quadrivalent live attenuated influenza vaccine (QLAIV), had lower than expected vaccine effectiveness (VE) against circulating A/H1N1pdm09 viruses in the USA. The underlying reason proposed for this was that the A/H1N1pdm09 vaccine strain, A/California/07/2009 (A/CA09), had a thermally unstable haemagglutinin (HA) protein. Consequently, a new A/H1N1pdm09 candidate strain, A/Bolivia/559/2013 (A/BOL13), was developed for inclusion in the 2015–2016 QLAIV. A key parameter for selection of A/BOL13 was its more thermostable HA phenotype compared with A/CA09. During the 2015–2016 season, QLAIV containing A/BOL13 was found in some studies to have improved, but still with suboptimal, VE against circulating A/H1N1pdm09 viruses and was not recommended for use by the CDC in the US market in the 2016–2017 influenza season. This suggested that improved HA thermostability had not entirely resolved the reduced VE observed. One hypothesis for this was that, by improving thermostability, the A/BOL13 HA protein had been over-stabilised, compromising its activation at the low endosomal pH required for successful viral entry. Here we demonstrate that, while the A/BOL13 HA protein is more stable than that of A/CA09, its thermal and pH stability were comparable with historically efficacious LAIV strains, suggesting that the HA had not been over-stabilised. Furthermore, studies simulating potential heat exposure during distribution by exposing QLAIV nasal sprayers to 33 °C for 4 h showed that, while remaining within product specification, A/CA09 viral potency was statistically decreased after 12 weeks at 2–8 °C. These data suggest that although unfavourable HA protein stability may have contributed to the reduced VE of A/CA09 in 2013–2014, it was unlikely to have affected A/BOL13 in 2015–2016. We conclude that HA stability was not the primary cause of the reduced effectiveness of LAIV against A/H1N1pdm09 viruses in the 2013–2014 and 2015–2016 seasons.
doi_str_mv 10.1016/j.vaccine.2019.06.016
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2253833412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X19307777</els_id><sourcerecordid>2253833412</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-660b1ce361ffb609418af98306e1657fef17042ec1bd15aad568b776746d37f33</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi0EokvhEUCWuHBJ6oljJzmhqqIsUgUXkLhZjjNevEqcJXYWlVPfgcfhbXgSnG7gwIXTeMbf_B7PT8hzYDkwkBf7_KiNcR7zgkGTM5mn6gOygbriWSGgfkg2rJBlVgL7fEaehLBnjAkOzWNyxqGoGiGrDfm51Tjo3a6fo_PO0xB163oXb-k3HagfI41fkB4mN-jplho9B6SjvS9O2M0GO4rWoonuiB5DWC77dKY6RvSzjglw3vYz-u-ariNTvdPOh0gvL7bwHg7dwBp6dFMSD4m-V0-_4r_ufqRQUu27JRenXNKAOow-PCWPrO4DPlvjOfl0_ebj1Ta7-fD23dXlTWbKksVMStaCQS7B2laypoRa26bmTCJIUVm0ULGyQANtB0LrTsi6rSpZlbLjleX8nLw66R6m8euMIarBBYN9rz2Oc1BFIXjNeQlFQl_-g-7HefJpuoWqJDAuIFHiRJlpDGFCq9YFK2BqcVft1boqtbirmFSpmvperOpzO2D3t-uPnQl4fQIwrePocFLBOPTJJTclj1Q3uv888Rv2u7mz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2257610351</pqid></control><display><type>article</type><title>Haemagglutinin stability was not the primary cause of the reduced effectiveness of live attenuated influenza vaccine against A/H1N1pdm09 viruses in the 2013–2014 and 2015–2016 seasons</title><source>ScienceDirect Freedom Collection (Elsevier)</source><source>ProQuest Central</source><creator>Parker, Lauren ; Ritter, Lydia ; Wu, Wen ; Maeso, Ruben ; Bright, Helen ; Dibben, Oliver</creator><creatorcontrib>Parker, Lauren ; Ritter, Lydia ; Wu, Wen ; Maeso, Ruben ; Bright, Helen ; Dibben, Oliver</creatorcontrib><description>During the 2013–2014 influenza season, the quadrivalent live attenuated influenza vaccine (QLAIV), had lower than expected vaccine effectiveness (VE) against circulating A/H1N1pdm09 viruses in the USA. The underlying reason proposed for this was that the A/H1N1pdm09 vaccine strain, A/California/07/2009 (A/CA09), had a thermally unstable haemagglutinin (HA) protein. Consequently, a new A/H1N1pdm09 candidate strain, A/Bolivia/559/2013 (A/BOL13), was developed for inclusion in the 2015–2016 QLAIV. A key parameter for selection of A/BOL13 was its more thermostable HA phenotype compared with A/CA09. During the 2015–2016 season, QLAIV containing A/BOL13 was found in some studies to have improved, but still with suboptimal, VE against circulating A/H1N1pdm09 viruses and was not recommended for use by the CDC in the US market in the 2016–2017 influenza season. This suggested that improved HA thermostability had not entirely resolved the reduced VE observed. One hypothesis for this was that, by improving thermostability, the A/BOL13 HA protein had been over-stabilised, compromising its activation at the low endosomal pH required for successful viral entry. Here we demonstrate that, while the A/BOL13 HA protein is more stable than that of A/CA09, its thermal and pH stability were comparable with historically efficacious LAIV strains, suggesting that the HA had not been over-stabilised. Furthermore, studies simulating potential heat exposure during distribution by exposing QLAIV nasal sprayers to 33 °C for 4 h showed that, while remaining within product specification, A/CA09 viral potency was statistically decreased after 12 weeks at 2–8 °C. These data suggest that although unfavourable HA protein stability may have contributed to the reduced VE of A/CA09 in 2013–2014, it was unlikely to have affected A/BOL13 in 2015–2016. We conclude that HA stability was not the primary cause of the reduced effectiveness of LAIV against A/H1N1pdm09 viruses in the 2013–2014 and 2015–2016 seasons.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2019.06.016</identifier><identifier>PMID: 31279567</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>2009 pandemic A/H1N1 (A/H1N1pdm09) ; Antigens ; Employees ; Genomes ; HA protein ; Haemagglutinin ; Hemagglutinins ; Hypotheses ; Influenza ; Licenses ; Live attenuated influenza vaccine ; Manufacturers ; Pandemics ; pH effects ; pH stability ; Phenotypes ; Product specifications ; Proteins ; Seasons ; Sprayers ; Thermal stability ; Thermostability ; Vaccine effectiveness ; Vaccine efficacy ; Vaccines ; Viruses</subject><ispartof>Vaccine, 2019-07, Vol.37 (32), p.4543-4550</ispartof><rights>2019 The Authors</rights><rights>Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><rights>2019. The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-660b1ce361ffb609418af98306e1657fef17042ec1bd15aad568b776746d37f33</citedby><cites>FETCH-LOGICAL-c440t-660b1ce361ffb609418af98306e1657fef17042ec1bd15aad568b776746d37f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2257610351?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31279567$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parker, Lauren</creatorcontrib><creatorcontrib>Ritter, Lydia</creatorcontrib><creatorcontrib>Wu, Wen</creatorcontrib><creatorcontrib>Maeso, Ruben</creatorcontrib><creatorcontrib>Bright, Helen</creatorcontrib><creatorcontrib>Dibben, Oliver</creatorcontrib><title>Haemagglutinin stability was not the primary cause of the reduced effectiveness of live attenuated influenza vaccine against A/H1N1pdm09 viruses in the 2013–2014 and 2015–2016 seasons</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>During the 2013–2014 influenza season, the quadrivalent live attenuated influenza vaccine (QLAIV), had lower than expected vaccine effectiveness (VE) against circulating A/H1N1pdm09 viruses in the USA. The underlying reason proposed for this was that the A/H1N1pdm09 vaccine strain, A/California/07/2009 (A/CA09), had a thermally unstable haemagglutinin (HA) protein. Consequently, a new A/H1N1pdm09 candidate strain, A/Bolivia/559/2013 (A/BOL13), was developed for inclusion in the 2015–2016 QLAIV. A key parameter for selection of A/BOL13 was its more thermostable HA phenotype compared with A/CA09. During the 2015–2016 season, QLAIV containing A/BOL13 was found in some studies to have improved, but still with suboptimal, VE against circulating A/H1N1pdm09 viruses and was not recommended for use by the CDC in the US market in the 2016–2017 influenza season. This suggested that improved HA thermostability had not entirely resolved the reduced VE observed. One hypothesis for this was that, by improving thermostability, the A/BOL13 HA protein had been over-stabilised, compromising its activation at the low endosomal pH required for successful viral entry. Here we demonstrate that, while the A/BOL13 HA protein is more stable than that of A/CA09, its thermal and pH stability were comparable with historically efficacious LAIV strains, suggesting that the HA had not been over-stabilised. Furthermore, studies simulating potential heat exposure during distribution by exposing QLAIV nasal sprayers to 33 °C for 4 h showed that, while remaining within product specification, A/CA09 viral potency was statistically decreased after 12 weeks at 2–8 °C. These data suggest that although unfavourable HA protein stability may have contributed to the reduced VE of A/CA09 in 2013–2014, it was unlikely to have affected A/BOL13 in 2015–2016. We conclude that HA stability was not the primary cause of the reduced effectiveness of LAIV against A/H1N1pdm09 viruses in the 2013–2014 and 2015–2016 seasons.</description><subject>2009 pandemic A/H1N1 (A/H1N1pdm09)</subject><subject>Antigens</subject><subject>Employees</subject><subject>Genomes</subject><subject>HA protein</subject><subject>Haemagglutinin</subject><subject>Hemagglutinins</subject><subject>Hypotheses</subject><subject>Influenza</subject><subject>Licenses</subject><subject>Live attenuated influenza vaccine</subject><subject>Manufacturers</subject><subject>Pandemics</subject><subject>pH effects</subject><subject>pH stability</subject><subject>Phenotypes</subject><subject>Product specifications</subject><subject>Proteins</subject><subject>Seasons</subject><subject>Sprayers</subject><subject>Thermal stability</subject><subject>Thermostability</subject><subject>Vaccine effectiveness</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkcFu1DAQhi0EokvhEUCWuHBJ6oljJzmhqqIsUgUXkLhZjjNevEqcJXYWlVPfgcfhbXgSnG7gwIXTeMbf_B7PT8hzYDkwkBf7_KiNcR7zgkGTM5mn6gOygbriWSGgfkg2rJBlVgL7fEaehLBnjAkOzWNyxqGoGiGrDfm51Tjo3a6fo_PO0xB163oXb-k3HagfI41fkB4mN-jplho9B6SjvS9O2M0GO4rWoonuiB5DWC77dKY6RvSzjglw3vYz-u-ariNTvdPOh0gvL7bwHg7dwBp6dFMSD4m-V0-_4r_ufqRQUu27JRenXNKAOow-PCWPrO4DPlvjOfl0_ebj1Ta7-fD23dXlTWbKksVMStaCQS7B2laypoRa26bmTCJIUVm0ULGyQANtB0LrTsi6rSpZlbLjleX8nLw66R6m8euMIarBBYN9rz2Oc1BFIXjNeQlFQl_-g-7HefJpuoWqJDAuIFHiRJlpDGFCq9YFK2BqcVft1boqtbirmFSpmvperOpzO2D3t-uPnQl4fQIwrePocFLBOPTJJTclj1Q3uv888Rv2u7mz</recordid><startdate>20190726</startdate><enddate>20190726</enddate><creator>Parker, Lauren</creator><creator>Ritter, Lydia</creator><creator>Wu, Wen</creator><creator>Maeso, Ruben</creator><creator>Bright, Helen</creator><creator>Dibben, Oliver</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20190726</creationdate><title>Haemagglutinin stability was not the primary cause of the reduced effectiveness of live attenuated influenza vaccine against A/H1N1pdm09 viruses in the 2013–2014 and 2015–2016 seasons</title><author>Parker, Lauren ; Ritter, Lydia ; Wu, Wen ; Maeso, Ruben ; Bright, Helen ; Dibben, Oliver</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-660b1ce361ffb609418af98306e1657fef17042ec1bd15aad568b776746d37f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>2009 pandemic A/H1N1 (A/H1N1pdm09)</topic><topic>Antigens</topic><topic>Employees</topic><topic>Genomes</topic><topic>HA protein</topic><topic>Haemagglutinin</topic><topic>Hemagglutinins</topic><topic>Hypotheses</topic><topic>Influenza</topic><topic>Licenses</topic><topic>Live attenuated influenza vaccine</topic><topic>Manufacturers</topic><topic>Pandemics</topic><topic>pH effects</topic><topic>pH stability</topic><topic>Phenotypes</topic><topic>Product specifications</topic><topic>Proteins</topic><topic>Seasons</topic><topic>Sprayers</topic><topic>Thermal stability</topic><topic>Thermostability</topic><topic>Vaccine effectiveness</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parker, Lauren</creatorcontrib><creatorcontrib>Ritter, Lydia</creatorcontrib><creatorcontrib>Wu, Wen</creatorcontrib><creatorcontrib>Maeso, Ruben</creatorcontrib><creatorcontrib>Bright, Helen</creatorcontrib><creatorcontrib>Dibben, Oliver</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Family Health</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Health Management</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest_Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parker, Lauren</au><au>Ritter, Lydia</au><au>Wu, Wen</au><au>Maeso, Ruben</au><au>Bright, Helen</au><au>Dibben, Oliver</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Haemagglutinin stability was not the primary cause of the reduced effectiveness of live attenuated influenza vaccine against A/H1N1pdm09 viruses in the 2013–2014 and 2015–2016 seasons</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2019-07-26</date><risdate>2019</risdate><volume>37</volume><issue>32</issue><spage>4543</spage><epage>4550</epage><pages>4543-4550</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>During the 2013–2014 influenza season, the quadrivalent live attenuated influenza vaccine (QLAIV), had lower than expected vaccine effectiveness (VE) against circulating A/H1N1pdm09 viruses in the USA. The underlying reason proposed for this was that the A/H1N1pdm09 vaccine strain, A/California/07/2009 (A/CA09), had a thermally unstable haemagglutinin (HA) protein. Consequently, a new A/H1N1pdm09 candidate strain, A/Bolivia/559/2013 (A/BOL13), was developed for inclusion in the 2015–2016 QLAIV. A key parameter for selection of A/BOL13 was its more thermostable HA phenotype compared with A/CA09. During the 2015–2016 season, QLAIV containing A/BOL13 was found in some studies to have improved, but still with suboptimal, VE against circulating A/H1N1pdm09 viruses and was not recommended for use by the CDC in the US market in the 2016–2017 influenza season. This suggested that improved HA thermostability had not entirely resolved the reduced VE observed. One hypothesis for this was that, by improving thermostability, the A/BOL13 HA protein had been over-stabilised, compromising its activation at the low endosomal pH required for successful viral entry. Here we demonstrate that, while the A/BOL13 HA protein is more stable than that of A/CA09, its thermal and pH stability were comparable with historically efficacious LAIV strains, suggesting that the HA had not been over-stabilised. Furthermore, studies simulating potential heat exposure during distribution by exposing QLAIV nasal sprayers to 33 °C for 4 h showed that, while remaining within product specification, A/CA09 viral potency was statistically decreased after 12 weeks at 2–8 °C. These data suggest that although unfavourable HA protein stability may have contributed to the reduced VE of A/CA09 in 2013–2014, it was unlikely to have affected A/BOL13 in 2015–2016. We conclude that HA stability was not the primary cause of the reduced effectiveness of LAIV against A/H1N1pdm09 viruses in the 2013–2014 and 2015–2016 seasons.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>31279567</pmid><doi>10.1016/j.vaccine.2019.06.016</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2019-07, Vol.37 (32), p.4543-4550
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_2253833412
source ScienceDirect Freedom Collection (Elsevier); ProQuest Central
subjects 2009 pandemic A/H1N1 (A/H1N1pdm09)
Antigens
Employees
Genomes
HA protein
Haemagglutinin
Hemagglutinins
Hypotheses
Influenza
Licenses
Live attenuated influenza vaccine
Manufacturers
Pandemics
pH effects
pH stability
Phenotypes
Product specifications
Proteins
Seasons
Sprayers
Thermal stability
Thermostability
Vaccine effectiveness
Vaccine efficacy
Vaccines
Viruses
title Haemagglutinin stability was not the primary cause of the reduced effectiveness of live attenuated influenza vaccine against A/H1N1pdm09 viruses in the 2013–2014 and 2015–2016 seasons
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A11%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Haemagglutinin%20stability%20was%20not%20the%20primary%20cause%20of%20the%20reduced%20effectiveness%20of%20live%20attenuated%20influenza%20vaccine%20against%20A/H1N1pdm09%20viruses%20in%20the%202013%E2%80%932014%20and%202015%E2%80%932016%20seasons&rft.jtitle=Vaccine&rft.au=Parker,%20Lauren&rft.date=2019-07-26&rft.volume=37&rft.issue=32&rft.spage=4543&rft.epage=4550&rft.pages=4543-4550&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2019.06.016&rft_dat=%3Cproquest_cross%3E2253833412%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2257610351&rft_id=info:pmid/31279567&rft_els_id=S0264410X19307777&rfr_iscdi=true